Published in Drug Week, April 28th, 2006
In a paper published in the Journal of Medicinal Chemistry, scientists in Illinois described the "development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-XL function."
"Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-microM binding but were strongly deactivated in the presence of serum," noted M.D. Wendt and coauthors at Abbott Laboratories. "The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA)."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.